Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib in pediatric Philadelphia chromosome-positive chronic myeloid leukemia
NL-OMON54687Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bosutinib in chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive chronic myeloid leukemia (2 arms), sponsored by Erasmus MC. Primary endpoints: Dose-limiting toxicities, Bosutinib pharmacokinetics and 2 more. Started Nov 2016; status: recruiting.
02
Drugs
bosutinib
03
Conditions
chronic myelogenous leukemia (CML)Philadelphia chromosome-positive chronic myeloid leukemia
Beyond the preview
Go deeper on NL-OMON54687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54687.